OR WAIT 15 SECS
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Revision Process for Global/National Pharmacopoeias (eBook)
J. Mark Wiggins is owner and compendial consultant with Global Pharmacopoeia Solutions LLC.
Joseph A. Albanese, director of Analytical Strategy and Compliance at Janssen Research and Development, LLC
This article describes the revision process and the resulting publication of proposed and official updates for pharmacopoeias around the world.
Pharmacopoeia Compliance Series
Compliance with requirements published by pharmacopoeias around the world is a legal and regulatory requirement for drug companies seeking to market products in that region. The multiple pharmacopoeias around the world are frequently revised and expanded, presenting challenges for bio/pharmaceutical companies that must monitor this activity.
This article examines the revision process of global and national pharmacopoeias, the publication schedules, and describes differences between the procedures of the various authorities.
This article is part of a series that will be published in 2019–2020. View all articles in this series.
Read this article in Pharmaceutical Technology’s December 2019 Regulatory Sourcebook.
Article Details
Pharmaceutical Technology
eBook: Regulatory Sourcebook, December 2019
December 2019
Pages: 17–25
Citation
When referring to this article, please cite it as J.M. Wiggins and J.A. Albanese, “Revision Process for Global/National Pharmacopoeias," Pharmaceutical Technology Regulatory Sourcebook eBook (December 2019).